NRD
VIR icon

Nebula Research & Development’s Vir Biotechnology VIR Stock Holding History

Nebula Research & Development’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-21,226
Closed -$138K – 1167
2025
Q1 		$138K Buy
21,226
+9,781
+85% +$87K 0.01% 893
2024
Q4 		$84K Buy
+11,445
New +$90.3K 0.01% 861

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nebula Research & Development's VIR Position: Q2 2025 in Review

Nebula Research & Development sold out of Vir Biotechnology (VIR) in Q2 2025, closing a stake of 21,226 shares — an estimated $138K sold.

Nebula Research & Development first reported a position in VIR in Q4 2024 and held it in 2 quarters. The position peaked at $138K in Q1 2025. 213 funds tracked by Wall St. Rank hold VIR as of Q2 2025.

  • Nebula Research & Development reported no remaining Vir Biotechnology position as of Q2 2025 after selling out during the quarter.
  • Nebula Research & Development sold 21,226 Vir Biotechnology shares in Q2 2025, an estimated $138K.
  • Nebula Research & Development first reported a position in Vir Biotechnology in Q4 2024 and held it in 2 quarters.
  • Nebula Research & Development's Vir Biotechnology position peaked at $138K in Q1 2025.
  • 213 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2025.

Based on Nebula Research & Development's 13F filing for Q2 2025, filed 14 Aug 2025.